Sangamo Therapeutics (SGMO) Reports Q2 Loss of $0.26

Sangamo Therapeutics (NASDAQ: SGMO) reported Q2 EPS of ($0.26), versus ($0.26) reported last year. Revenue for the quarter came in at $21.55 million, versus $17.55 million reported last year.

For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c